AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 271: H88-H93, 1996;
0363-6135/96 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, J. S.
Right arrow Articles by Schiffrin, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, J. S.
Right arrow Articles by Schiffrin, E. L.

AJP - Heart and Circulatory Physiology, Vol 271, Issue 1 88-H93, Copyright © 1996 by American Physiological Society

ARTICLES

Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats

J. S. Li, L. Knafo, A. Turgeon, R. Garcia and E. L. Schiffrin
Medical Research Council of Canada Multidisciplinary Research Group on Hypertension, University of Montreal, Quebec, Canada.

To investigate the potential pathogenic role of endothelin in blood pressure elevation and vascular hypertrophy in renovascular hypertensive rats, which present twofold elevations in endothelin-1 mRNA abundance in blood vessels, the response of blood pressure and vascular structure to chronic treatment with the endothelin receptor antagonist bosentan was evaluated. One-kidney, one clip (1K,1C) and two kidney, one clip (2K,1C) Goldblatt hypertensive rats were treated for 2 wk with bosentan (100 mg.kg-1.day-1) in their chow, and systolic blood pressure was measured by the tail-cuff method. Vascular structure was studied in small arteries mounted on a wire myograph. Treatment with bosentan did not result in a significant change in systolic blood pressure or in the structure of small coronary, renal cortical, mesenteric, or femoral arteries in 1K, 1C or in 2K, 1C hypertensive rats. In conclusion, modest (twofold) elevations of endothelin-1 gene expression in blood vessels in renovascular hypertension are not associated with hypotensive responses or regression of vascular hypertrophy during treatment with endothelin antagonists in contrast to what is found in deoxycorticosterone acetate salt hypertensive rats, which exhibit very dramatic increases in endothelin-1 expression (five-to eightfold) and do respond to endothelin antagonism with blood pressure lowering and regression of vascular hypertrophy. These small elevations of vascular endothelin-1 gene expression thus do not appear to indicate the presence of an endothelin component in blood pressure elevation in renovascular hypertension in rats.


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
Y. Suzuki, O. Lopez-Franco, D. Gomez-Garre, N. Tejera, C. Gomez-Guerrero, T. Sugaya, R. Bernal, J. Blanco, L. Ortega, and J. Egido
Renal Tubulointerstitial Damage Caused by Persistent Proteinuria Is Attenuated in AT1-Deficient Mice : Role of Endothelin-1
Am. J. Pathol., November 1, 2001; 159(5): 1895 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. M. Touyz and E. L. Schiffrin
Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells
Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. F. Luscher and M. Barton
Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs
Circulation, November 7, 2000; 102(19): 2434 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. N. Muller, E. M. A. Mervaala, F. Schmidt, J.-K. Park, R. Dechend, E. Genersch, V. Breu, B.-M. Loffler, D. Ganten, W. Schneider, et al.
Effect of Bosentan on NF-{kappa}B, Inflammation, and Tissue Factor in Angiotensin II-Induced End-Organ Damage
Hypertension, August 1, 2000; 36(2): 282 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G. P. Rossi, A. Sacchetto, D. Rizzoni, S. Bova, E. Porteri, G. Mazzocchi, A. S. Belloni, M. Bahcelioglu, G. G. Nussdorfer, and A. C. Pessina
Blockade of Angiotensin II Type 1 Receptor and Not of Endothelin Receptor Prevents Hypertension and Cardiovascular Disease in Transgenic (mREN2)27 Rats via Adrenocortical Steroid-Independent Mechanisms
Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 949 - 956.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
Y. Ono, H. Ono, H. Matsuoka, T. Fujimori, and E. D. Frohlich
Apoptosis, Coronary Arterial Remodeling, and Myocardial Infarction After Nitric Oxide Inhibition in SHR
Hypertension, October 1, 1999; 34(4): 609 - 616.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Ehmke, J. Faulhaber, K. Munter, M. Kirchengast, and R. J. Wiesner
Chronic ETA Receptor Blockade Attenuates Cardiac Hypertrophy Independently of Blood Pressure Effects in Renovascular Hypertensive Rats
Hypertension, April 1, 1999; 33(4): 954 - 960.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
B. Hocher, I. George, J. Rebstock, A. Bauch, A. Schwarz, H.-H. Neumayer, and C. Bauer
Endothelin System–Dependent Cardiac Remodeling in Renovascular Hypertension
Hypertension, March 1, 1999; 33(3): 816 - 822.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online